selective calcium channel blockers	target	vascular smooth muscle
selective calcium channel blockers	inhibit	L-type calcium channels
L-type calcium channels	mediate	vasoconstriction
vasoconstriction	reduces	blood pressure
blood pressure	lowers	hypertension
hypertension	increases	cardiovascular risk
cardiovascular risk	mitigated by	calcium channel blockers
calcium channel blockers	cause	peripheral edema
peripheral edema	managed by	diuretics
diuretics	reduce	edema
selective calcium channel blockers	have	minimal cardiac effects
minimal cardiac effects	benefit	heart failure patients
heart failure patients	benefit from	vasodilators
vasodilators	improve	exercise tolerance
exercise tolerance	predicts	mortality
mortality	decreases	with better exercise tolerance
selective calcium channel blockers	contraindicated in	severe aortic stenosis
severe aortic stenosis	requires	valve replacement
valve replacement	improves	survival
selective calcium channel blockers	metabolized by	CYP3A4
CYP3A4 inhibitors	increase	drug levels
increased drug levels	cause	hypotension
hypotension	leads to	syncope
syncope	increases	fall risk
fall risk	predicts	readmission
readmission	reduces	quality of life
quality of life	measured by	SF-36
SF-36	scores	improve with therapy
therapy	includes	calcium channel blockers
selective calcium channel blockers	have	low hepatotoxicity
low hepatotoxicity	suitable for	liver disease
liver disease	requires	dose adjustment
dose adjustment	guided by	liver function tests
liver function tests	include	ALT
ALT	elevated	indicates hepatotoxicity
hepatotoxicity	contraindicates	drug use
drug use	monitored by	therapeutic drug monitoring
therapeutic drug monitoring	ensures	therapeutic range
therapeutic range	associated with	efficacy
efficacy	reduces	hospitalization
hospitalization	predicts	mortality
mortality	reduced by	blood pressure control
blood pressure control	achieved by	calcium channel blockers
calcium channel blockers	improve	endothelial function
endothelial function	measured by	flow-mediated dilation
flow-mediated dilation	predicts	cardiovascular events
cardiovascular events	include	myocardial infarction
myocardial infarction	treated with	reperfusion therapy
reperfusion therapy	improves	survival
survival	linked to	medication adherence
medication adherence	measured by	pharmacy refill data
pharmacy refill data	predicts	adherence
adherence	influences	blood pressure variability
blood pressure variability	predicts	stroke
stroke	prevented by	antihypertensives
antihypertensives	include	calcium channel blockers
calcium channel blockers	have	low drug–drug interaction profile
low drug–drug interaction	beneficial for	polypharmacy
polypharmacy	common in	elderly
elderly	at risk for	falls
falls	associated with	orthostatic hypotension
orthostatic hypotension	caused by	vasodilators
vasodilators	include	calcium channel blockers
calcium channel blockers	have	dihydropyridine subclass
dihydropyridine subclass	includes	amlodipine
amlodipine	indicated for	hypertension
amlodipine	improves	arterial compliance
arterial compliance	measured by	pulse wave velocity
pulse wave velocity	predicts	cardiovascular mortality
cardiovascular mortality	reduced by	antihypertensive therapy
antihypertensive therapy	guided by	JNC guidelines
JNC guidelines	recommend	calcium channel blockers
calcium channel blockers	used in	resistant hypertension
resistant hypertension	defined by	uncontrolled BP
uncontrolled BP	leads to	end‑organ damage
end‑organ damage	includes	left ventricular hypertrophy
left ventricular hypertrophy	treated with	antihypertensives
antihypertensives	reduce	LVH
LVH	associated with	arrhythmias
arrhythmias	treated with	antiarrhythmic drugs
antiarrhythmic drugs	contraindicated with	calcium channel blockers
contraindicated	due to	QT prolongation
QT prolongation	monitored by	ECG
ECG	shows	QT interval
QT interval	prolonged by	drug interactions
drug interactions	avoided by	medication review
medication review	improves	safety
safety	reduces	adverse events
adverse events	decrease	readmission
readmission	tracked by	hospital data
hospital data	used for	quality improvement
quality improvement	focuses on	medication safety
medication safety	enhanced by	clinical decision support
clinical decision support	alerts for	drug interactions
alerts	improve	prescribing behavior
prescribing behavior	influences	patient outcomes
patient outcomes	measured by	composite endpoint
composite endpoint	includes	mortality	readmission	adverse events
mortality	readmission	adverse events	all reduced by	effective antihypertensive therapy
effective antihypertensive therapy	exemplified by	selective calcium channel blockers
